![FDA approves a second Alzheimer’s drug that can modestly slow disease](https://npr.brightspotcdn.com/dims3/default/strip/false/crop/3000x2000+0+0/resize/3000x2000!/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Ffa%2F56%2Feeeab5324cfda41b2715edbcf10e%2Fap24184513211915.jpg)
The approval of Eli Lilly’s Kisunla provides a new option for patients in the early stages of the incurable, memory-destroying ailment.
(Image credit: AP)
NPR Topics: News Read More
The approval of Eli Lilly’s Kisunla provides a new option for patients in the early stages of the incurable, memory-destroying ailment.
(Image credit: AP)
NPR Topics: News Read More